Braintree in-licenses global rights to oncology drug platform.

Braintree Laboratories, Inc. (Braintree, MA) has in-licensed the global rights to develop and commercialize BLI-600, a patent protected compound that has shown significant promise as a chemoprevention agent, from INRA Transfert (IT), a subsidiary of National Institute for Agricultural Research (Paris, France). Under the terms of the agreement, Braintree Laboratories is responsible for the clinical development and worldwide registration of the compound for chemoprevention and/or treatment of colorectal cancer.

The Foods & Cancer team of the joint research group ENVT-INRA Xenobiotics managed by Pr Denis Corpet, leader in the field of food and colon carcinogenesis, has tested BLI-600 in several in-vivo animal models and has demonstrated a strong signal for both eliminating and preventing adenomas …